Guide
Tirzepatide and Muscle Loss: What the Body-Composition Data Shows
Sub-studies using DEXA imaging report that roughly a quarter to two-fifths of total weight lost on a GLP-1 is lean mass — a proportion broadly similar to other rapid weig
Sub-studies using DEXA imaging report that roughly a quarter to two-fifths of total weight lost on a GLP-1 is lean mass — a proportion broadly similar to other rapid weight-loss methods rather than unique to these drugs. What is not established is the long-term functional consequence.
What do the imaging sub-studies report?
| Method | Lean share of loss | Evidence base |
|---|---|---|
| GLP-1 pharmacotherapy | ~25–40% | DEXA sub-studies |
| Caloric restriction alone | ~20–30% | Long-standing literature |
| Bariatric surgery | ~20–30% | Long-standing literature |
Ranges vary by study, population and imaging method. Treat the direction as the finding, not the percentages as precise.
“GLP-1s destroy muscle” is not what the data says. The lean-mass share of loss looks broadly comparable to other rapid weight-loss routes.
What is genuinely unsettled is the functional consequence over years — strength, mobility, fall risk in older patients. That question does not have an answer yet, and a page claiming one is inventing it.
What is reasonable and what is extrapolation?
Adequate protein intake and resistance training are standard advice during any substantial weight loss, on solid general evidence. Applying that to GLP-1 patients is reasonable inference, not a GLP-1-specific trial result, and we will label it that way rather than dress it up.
We are not publishing gram-per-kilogram targets or a training protocol. Those are individual, and for older patients in particular they belong with a clinician.
Does the drug choice change the picture?
No published head-to-head has compared body composition between tirzepatide and semaglutide as a primary endpoint. SURMOUNT-5 compared total weight loss, 20.2% against 13.7%, and did not answer the lean-mass question.
| Trial | Population | Result | Duration |
|---|---|---|---|
| SURMOUNT-1 | Obesity or overweight, no diabetes | 22.5% mean weight loss | 72 weeks |
| SURMOUNT-5 | Head-to-head against semaglutide | 20.2% vs 13.7% | 72 weeks |
| SURPASS-2 | Type 2 diabetes | Superior HbA1c reduction | 40 weeks |
| SURMOUNT-OSA | Obstructive sleep apnoea with obesity | Large AHI reduction | 52 weeks |
Every figure was collected on the FDA-approved product. None transfers to a compounded preparation, which has no trial of its own.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| Mochi Health | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| NexLife | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.
That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.
Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
Does tirzepatide cause muscle loss?
Imaging sub-studies report roughly a quarter to two-fifths of total weight lost is lean mass, broadly comparable to caloric restriction and bariatric surgery rather than unique to GLP-1s.
What is not known about muscle loss on GLP-1s?
The long-term functional consequence — strength, mobility and fall risk over years — is not established.
Does tirzepatide preserve muscle better than semaglutide?
No published head-to-head has tested body composition as a primary endpoint. SURMOUNT-5 compared total weight loss only.
Related on this site
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- Ro Body vs Hims & HersComparisons
- Hims & Hers vs Henry MedsComparisons
- Brand-Name vs Compounded TirzepatidePillar / Money
- Hims & Hers Tirzepatide ReviewProviders
- Compounded vs Brand Tirzepatide: Legal and Evidence DifferencesJournal
- Zepbound vs MounjaroComparisons
- Tirzepatide for Type 2 DiabetesResearch
Related coverage
- Tirzepatide and Alcohol: What Patients Report and What Is Established
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- SURMOUNT-5 Published: Tirzepatide 20.2% Against Semaglutide 13.7% in the First Head-to-Head
- SYNCHRONIZE-1: 16.6% Weight Loss With 34% Less Visceral Fat and 63% Less Liver Fat
- The Tirzepatide Shortage Delisting Was Not One Date — It Was a Year of Litigation
- Telehealth group agrees consent judgment of up to $600,000 over controlled substance allegations
- TrumpRx Launches Direct GLP-1 Pricing, Undercutting List Prices by Up to Nine Times
- FDA Approves the Wegovy Pill: Oral Semaglutide 25 mg for Weight Management
GLP-1 Tirzepatide Rank. “Tirzepatide and Muscle Loss: What the Body-Composition Data Shows.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/tirzepatide-and-muscle-loss-2026/
Quote the capture date beside a figure, not the date you read this page. Why.